Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI EV / sales

EV / sales at other companies

Eli Lilly logo
Eli LillyLLY
11.9×-4.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.5×+0.6×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
2.7×-4.0×
uniQure logo
uniQureQURE
52.3×+31.4×
Biogen logo
BiogenBIIB
3×+0.8×
PTC Therapeutics logo
PTC TherapeuticsPTCT
6.3×+4.6×

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Calculated from Denali Therapeutics Inc.’s reported figures.

enterprise value/total revenue=2,591.9×

Based on the most recent quarter.

The official record: Denali Therapeutics Inc.’s 10-Q, filed August 11, 2025, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s EV / sales?
Denali Therapeutics Inc. (DNLI) reported EV / sales of 2,591.9× in Q2 2024.
How has Denali Therapeutics Inc.'s EV / sales changed year-over-year?
Denali Therapeutics Inc.'s EV / sales increased by 22347.7% year-over-year, from 11.5× to 2,591.9×.
What is the long-term trend for Denali Therapeutics Inc.'s EV / sales?
Over 3 years (2020 to 2023), Denali Therapeutics Inc.'s EV / sales has grown at a -33.1% compound annual growth rate (CAGR), from 29.2× to 8.7×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.